Antibodies capable of blocking the binding of B7-H1 and PD-1 have been used in clinical trials in treatment of various cancers in humans4, 5, and recently one anti-PD-L1 antibody (atezolizumab) has been approved to treat bladder cancers. Here, CD274 is linked to cancer.